Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33090438&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis #MMPMID33090438
Akhter N; Ahmad S; Alzahrani FA; Dar SA; Wahid M; Haque S; Bhatia K; Sr Almalki S; Alharbi RA; Sindi AAA
Eur Rev Med Pharmacol Sci 2020[Oct]; 24 (19): 10267-10278 PMID33090438show ga
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) uses Angiotensin- converting enzyme 2 (ACE2) receptors to infect host cells which may lead to coronavirus disease (COVID-19). Given the presence of ACE2 receptors in the brain and the critical role of the renin-angiotensin system (RAS) in brain functions, special attention to brain microcirculation and neuronal inflammation is warranted during COVID-19 treatment. Neurological complications reported among COVID-19 patients range from mild dizziness, headache, hypogeusia, hyposmia to severe like encephalopathy, stroke, Guillain-Barre Syndrome (GBS), CNS demyelination, infarcts, microhemorrhages and nerve root enhancement. The pathophysiology of these complications is likely via direct viral infection of the CNS and PNS tissue or through indirect effects including post- viral autoimmune response, neurological consequences of sepsis, hyperpyrexia, hypoxia and hypercoagulability among critically ill COVID-19 patients. Further, decreased deformability of red blood cells (RBC) may be contributing to inflammatory conditions and hypoxia in COVID-19 patients. Haptoglobin, hemopexin, heme oxygenase-1 and acetaminophen may be used to maintain the integrity of the RBC membrane.
|*Hemolysis/drug effects[MESH]
|Brain/blood supply/*physiopathology[MESH]
|COVID-19/complications/*physiopathology[MESH]
|Erythrocytes/drug effects/*pathology[MESH]
|Humans[MESH]
|Models, Neurological[MESH]
|Molecular Targeted Therapy/methods[MESH]
|Nervous System Diseases/complications/drug therapy/*physiopathology[MESH]
Eur+Rev+Med+Pharmacol+Sci 2020 ; 24 (19): 10267-10278
